News|Articles|March 5, 2026

FDA Action Update, February 2026: Complete Response Letter, Expanded Indication, and Acceptance

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

The FDA was busy in February 2026, making a number of decisions on potential new therapeutic agents, including issuing a complete response letter (CRL), granting an expanded approval indication, accepting a new drug application (NDA), and granting a priority review.